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ABBREVIATIONS
aGVHD, acute graft-versus-host disease
AML, acute myeloid leukemia
APC, antigen presenting cell
APL, acute promyelocytic leukemia
BMT, bone marrow transplantation
BSA, bovine serum albumin
CB1093, 1(S), 3(R)-Dihydroxy-20(R)-(1(S)-1-ethoxy-5-ethyl-5-hydroxy-2-
heptyn-1-yl)-9,10-seco-pregna-5(Z), 7(E), 10(19)-triene
Cdk, cyclin-dependent kinase
CR, complete remission
CsA, cyclosporin A
DLI, donor lymphocyte infusion
EAE, murine experimental autoimmune encephalomyelitis
EB1089, 24a,26a,27a-tri-homo-22,24-diene-1-alfa,25-(OH)2-D3
FK506, tacrolimus
GVHD, graft-versus-host disease
HLA, human leukocyte antigen
HSCT, hematopoietic stem cell transplantation
IL-2, interleukin-2
MC1288, 20-epi-1,25(OH)2D3
MLC, mixed lymphocyte culture
MMF, mycophenolate mofetil
NK cell, natural killer cell
PHA, phytohemagglutin
RA, retinoic acid
RAR, retinoic acid receptor
RARE, retinoic acid-responsive element
RXR, retinoid X receptor
SCT, stem cell transplantation
TCR, T cell receptor
TNF, tumor necrosis factor
VD3, 1α25(OH)2D3, the active form of vitamin D3
VDR, vitamin D3 receptor
VDRE, vitamin D3-responsive element
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INTRODUCTION
In the treatment of acute leukemia there are two main problems. After
chemotherapy, the long term results in maintenance therapy have not
improved. Another way to treat acute leukemia is stem cell transplantation in
which acute graft-versus-host disease is a major cause of mortality. Novel
vitamin D analogs have demonstrated both antileukemic and
immunosuppressive properties. This provides possible alternatives to current
practice.
A differentiation therapy suitable for clinical use would decisively change the
treatment practice of acute myeloid leukemia. This has already happened in the
treatment of acute promyelocytic leukemia where  patients can achieve
remission using retinoic acid (RA) without the side effects of chemotherapy.
Stem cell transplantation is the common practice in leukemia for patients with
a suitable donor. Main problems arise from acute graft-versus-host disease
(aGVHD), which necessitates long treatment periods and high dose use of
steroids. Due to lack of suitable related donors the use of unrelated, HLA-
matched donors from international marrow-donor registries has increased.
This has lead to a better prognosis in the treatment of leukemia itself, due to
graft-versus-leukemia effect, but with the cost of higher incidence of GVHD.
In solid organ transplantation many transplants are lost due to chronic
rejection (transplant arteriosclerosis). The medication used for chronic rejection
today has marked side effects that severely limit the immunosuppressive effect
that can be induced with these drugs. We need to develop new
immunosuppressive strategies that minimize side effects but still are potential
in preventing graft rejection.
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REVIEW OF THE LITERATURE
1. Background
1.1 Acute myeloid leukemia
The hematopoietic system produces blood cells by committing required stem
cells into maturation. These committed cells lose their ability to divide while
they mature into functional blood cells. The stem cells are self-renewable and
normally preserved in a non-cycling state.
The prominent abnormality of acute myeloid leukemia (AML) is the inability of
the cells to differentiate to functional mature cells. The maturation of the cells is
blocked at an early stage and the cells remain in a rapidly dividing proliferative
pool. Thus, AML is characterized by the proliferation of abnormal leukemic
blast cells, and impaired production of normal blood cells, leaving the patient
prone to anemia, thrombocytopenia, neutropenia, and bleeding as well as
infection.
Treatment of AML is based on cytotoxic chemotherapy, differentiation therapy,
and stem cell transplantation (SCT). The  aim in chemotherapy is to suppress
the leukemic cells to an inapparent level, in order to permit the normal
polyclonal hematopoiesis.  Differentiation therapy aims to promote cell
maturation towards forms that lose their ability to proliferate in an
uncontrolled fashion.  In contrast, in SCT the sick bone marrow is replaced
with a healthy one from the donor. All these treatments may eventually cure
the patient.
1.2 Chemotherapy in the treatment of AML
AML is a marrow-based neoplasm where normal blood cells are replaced by
malignant blasts. In most cases these blasts differentiate towards myeloid or
monocytic lineage. Antileukemic therapy based on chemotherapy results in
complete remission (CR) rates varying between 60 and 75%. It has proven
difficult to improve the CR rates achieved with the different combinations of
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cytarabine and anthracyclines. Long-term disease-free survival occurs in 25-
50% of CR patients depending on post-remission therapy employed (Berman et
al., 1991; Phillips et al., 1991; Schiffer et al., 1997; Zittoun et al., 1989).
1.3 Differentiation therapy
Another approach in achieving CR is differentiation therapy, where cells lose
their ability to proliferate as they mature (Koeffler, 1983).
This approach has been proven to lead to remission in acute promyelocytic
leukemia, where retinoic acid induce terminal differentiation of promyelocytic
cells (Castaigne et al., 1990; Chen et al., 1991; Huang et al., 1988; Warrell et al.,
1991). It has also been demonstrated that vitamin D analogs have an
antileukemic effect in vitro and in vivo in mice (Honma et al., 1983; Zhou et al.,
1990). Unfortunately, most of the vitamin D analogs raise the calcium level in
blood, which has lead to hypercalcemia before antileukemic concentrations in
blood have been reached (Koeffler et al., 1985).
1.4 Stem cell transplantation
The first successful bone marrow transplantations (BMT) were performed from
human leukocyte antigen (HLA)-identical siblings in 1968 (Bach et al., 1968).
Since then, what was once an experimental procedure has become established
therapy. Traditional BMT from HLA-matched relatives has been supplemented
with new methods of collecting hematopoietic stem cells from variety of
sources and donors. Today, the stem cells can be harvested from bone marrow,
peripheral blood, cord blood, and rarely fetal liver. The donor can be the
patient him/herself (autologous transplant), an HLA-identical sibling or an
HLA-matched volunteer (allogeneic transplant) perhaps living on a different
continent.
Hematopoietic stem cell transplantation (HSCT) is increasingly used to treat
both malignant and nonmalignant diseases (Goldman et al., 1998; Gratwohl et
al., 2000; Tyndall and Gratwohl, 1997). Main indications in Europe 1998 were
leukemias (33%), lymphomas (41%, mostly autologous), solid tumors (22%,
99% autologous) and non-malignant disorders (5%, 80% allogeneic). Absolute
number of transplants per year has increased from 4234 in 1990 to 20892 in
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1998 (Gratwohl et al., 2000). Due to lack of suitable related donors the
proportion of unrelated, HLA-matched donors from international marrow-
donor registries has increased.
1.5 Graft-versus-host disease (GVHD) and graft failure
The recognition of cells as self/foreign is based on histocompatibility antigens
(Bach and Sachs, 1987). The HLA class I and II regions on chromosome 6
contain the most polymorphic genes in the human genome (Bodmer et al.,
1999; Mach, 1994). The three class I (HLA-A, -B, -C) and eight class II (HLA-
DRB1, -DRB3, -DRB4, DRB5, -DQA1, -DQB1, -DPA1, -DPB1) genes act as
histocompability antigens causing transplantation barriers in stem cell
transplantation as well as in solid organ transplantation. At least 456 different
class I and 420 different class II alleles have been identified (Bodmer et al.,
1999). This variability leads to the fact that it is extremely unlikely to find an
HLA-identical, unrelated donor.
Antigens are recognized by T-cells only in conjunction with major
histocompatibility complex (MHC), referred to as HLA in humans. In
allogeneic SCT the immunocompetent cells within the graft react to host
antigens, thus causing GVHD.
Increasing use of unrelated HLA-matched donors has leaded to higher
incidence of GVHD (Ferrara and Deeg, 1991), that is a major cause of mortality
and morbidity in these patients. Approximately 75% of transplant-related
deaths are associated with GVHD (Brown et al., 1999) . Recently, a major goal
has been to develop better HLA-typing techniques and new more effective
prophylactic and therapeutic regimens that would overcome GVHD.
The most logical step to overcome GVHD is to identify and remove the main
culprits, namely, T-cells. Therefore in the 1980s there was an attempt to deplete
the T-cells from donor marrow to prevent GVHD. However, this has since been
associated with a high risk of relapse (Goldman et al., 1988). The curative effect
of allogeneic transplantation is, at least partly, mediated by graft-versus-
leukemia effect. The hypothesis is further supported by the inverse correlation
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between relapse and severity of GVHD (van Rhee et al., 1997), and by the
observation that donor lymphocyte infusion can restore normal donor
hematopoiesis in patients who have relapsed after allogeneic SCT (Apperley et
al., 1998).
In conclusion, although T-cell depletion effectively prevents GVHD, it has an
adverse effect on stem cell engraftment and increases the possibility of graft
failures. GVHD is a major cause of mortality in allogeneic SCT, but some of it
must be tolerated as it coexists with the vital graft-versus-leukemia effect.
1.6 Rejection of solid organ transplants
Transplantation of foreign tissue into a recipient leads to an antigen-specific
immune response and non-specific inflammatory response. In graft rejection
the main concern is the antigen-specific immune response, but this is amplified
by the inflammatory response. The specific immune response is mediated by T
cells and antibody-producing B cells. T cell activation is a key event in the
immune response. Once activated by the antigen, T cells induce the
differentiation and activation of various other cells.
T cells do not recognize free antigen, but short peptides presented by the
antigen presenting cells (APC).  These peptides become associated with MHC
molecules of the APC prior to their transport to APC cell surface and the
presentation to T cells. MHC class I molecules present peptides derived from
endogenous proteins and are recognized by CD8 molecules on cytotoxic T cells.
MHC class II molecules bind exogenous peptides and are recognized by CD4
molecules on helper T cells (Doyle and Strominger, 1987).
In direct presentation, recipient T cells recognize foreign peptides presented by
donor APCs. These are mostly donor dendritic cells, bearing both MHC class I
and II antigens, and rapidly migrating from the graft to recipient's lymphoid
tissue. In indirect presentation, recipient T cells recognize foreign peptides
processed and presented by recipient APCs.
T cell activation requires costimulatory signals. T cell receptor (TCR) linked
with CD3 molecule binds to MHC-antigen complex expressed by the APC.
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CD4/CD8 binds with MHC molecule and associates with TCR-CD3 complex.
In addition, effective T cell activation requires costimulatory signals from
CD28-B7 interaction and/or CD40-CD40 ligand interaction (Linsley et al., 1990;
Sayegh and Turka, 1998). The activation of T cell is initiated when a required
treshold number of triggered TCRs is reached. This treshold number varies
depending whether costimulation exists (Viola and Lanzavecchia, 1996).
When CD28-B7 mediated costimulation is present, treshold number of
triggered TCRs can be downregulated from 8000 to 1000 (Viola and
Lanzavecchia, 1996). Cells able to provide CD28 costimulation are professional
APCs such as macrophages and dendritic cells. These cells present the foreign
antigen to T cells in lymphatic tissues. Recent research has focused on the
mechanism of TCR activation in the constraints of APC and T cell membranes.
The evidence indicates that many signaling components, such as Lck and LAT,
are concentrated in cholesterol-enriched membrane microdomains, called rafts
(Simons and Ikonen, 1997). Two studies demonstrated that rafts are required
for efficient T cell activation and activated TCRs are recruited to the rafts
(Montixi et al., 1998; Xavier et al., 1998).
B cells bind native antigen directly with their surface immunoglobulin
receptors. The antigen is internalized, processed and presented with MHC class
II molecule to CD4+ T cells. Activated T cells express CD40 ligand, which
interacts with the CD40 molecule on the B cell, thus activating it (Linsley et al.,
1990). The activated B cells proliferate and produce antibodies. Some B cells
differentiate to plasma cells producing large amount of antibodies before their
demise. Other B cells differentiate to memory B cells (Campbell and Halloran,
1996).
Rejection can be divided to hyperacute, acute and chronic rejection.
Hyperacute rejection is mediated by preformed recipient antibodies to donor
ABO blood group, MHC antigens or alpha-Gal epitope (Auchincloss and Sachs,
1998; Robson et al., 1999). Antibodies bind to graft causing fixation of
complement, and attracting neutrophils (Hall and Suranyi, 1995; Hernandez-
Fuentes et al., 1999). Complement forms a membrane attack complex (MAC),
which causes an ion permeable hole to graft endothelial cell surface, thus
disrupting the form and function of the cell membrane (Liszewski et al., 1996).
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The result is rapid occlusion of the vasculature following widespread
endothelial destruction, culminating in rapid graft failure. This is a rare
phenomenon due to cross-matching tests done prior to the transplantation.
Acute graft rejection is mediated by T cells. Nude mice and T cell deprived
animals fail to reject xeno- or allografts. Of the T cells, CD4+ cells have been
found to be critical in initiating rejection. After the activation of the immune
system many cells contribute to the acute rejection. Clinically the hallmark of
acute rejection is a cellular infiltrate. This consists predominantly of small
activated lymphocytes and monocytes/macrophages with some plasma cells,
neutrophils and eosinophils. The infiltrate is histologically mostly perivascular
with increasing manifestations in surrounding tissues as the rejection
progresses (Hall and Suranyi, 1995). There is some question to the role of
cytotoxic T cells and natural killer (NK) cells in acute graft rejection, although
NK cells have clearly been shown to be involved in the rejection of bone
marrow transplants (Yu et al., 1992).
Chronic rejection is characterized by vascular injury in the graft.
Manifestations are fibrointimal arterial narrowing with surrounding tissue
showing signs of ischemia.  In cardiac transplants the process is atherosclerosis
of coronary arteries. The lesions are less focal than in classical atherosclerosis
(James et al., 2001; Paavonen et al., 1993). In renal grafts chronic rejection
manifestates as interstitial fibrosis, tubular atrophy, glomerular sclerosis and
basement membrane reduplication. De novo membranous glomerulopathy
may also be a form of chronic rejection.  All arteries  in the transplanted kidney
are affected by this process as can be demonstrated by angiography (Ponticelli,
2000). In liver grafts biliary ducts disappear in addition to arterial injury
(Lowes et al., 1993). In lung grafts there is bronchiolar injury with bronchiolar
occlusion (Boehler and Estenne, 2000; Date, 2001; Elssner and Vogelmeier,
2001).
In histology and immunohistochemistry T cells and macrophages can be
identified, but not to the extent that can be seen in the infiltration of acute
rejection. IgG and components of complement can also be found in the vessel
walls. Common to all grafts is injury to vascular endothelium. Vascular
endothelium of the graft is readily presented to host T cells and expresses the
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ligands needed to activate and adhere them (class I and II MHC and ICAM-1).
The endothelial cells can express surface molecules to facilitate the migration of
lymphocytes and macrophages to surrounding tissues. Coagulation factors and
growth factors such as platelet-derived growth factor (PDGF) and thrombin
stimulate the growth of smooth muscle cells and fibroblasts. The "Response to
injury" (Ross, 1993) hypothesis suggests that alloimmune-induced injury to the
graft is low grade and repetitive, where repair and recovery is slower and can
not keep pace with the injury.  The manifestations of the injury are
characteristic in each organ. These include obliterative bronchiolitis in lungs,
glomerular injury in kidneys, and biliar injury in livers. The injury in chronic
rejection may be difficult to differentiate from drug toxicity (e.g. cyclosporin in
the kidney) or recurrence of the disease (e.g. atherosclerosis in the heart and
primary biliary cirrhosis in the liver).
1.7 Limitations of immunosuppressive agents
Clinical immunosuppression has made giant steps of progress during the last
two decades. The short term results are quite remarkable in preventing acute
rejection and graft loss but the long term results have not been improved over
the past two decades. Regardless of this development, chronic rejection
(transplant arteriosclerosis) and chronic graft dysfunction remain a problem.
Cyclosporin A combined with other immunosuppressive drugs forms the
backbone of modern immunosuppressive treatment. Cyclosporin and
tacrolimus may, albeit very effective in the prevention of acute rejection, cause
graft dysfunction through scarring, particularly in kidneys (Mihatsch et al.,
1998; Solez et al., 1998).
A new direction of low-toxicity immunosuppression has emerged. The goal is
to minimize the severe side effects of drugs in use today: nephrotoxicity,
neurotoxicity, development of cardiovascular diseases, infection, malignancy
and adverse cosmetic changes.
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Table 1. Immunosuppressive agents, their mechanism of action, and side effects
Cyclosporin A,
CsA
Binds to cyclophilin. CsA
cyclophilin complex blocks
calcineurin-calmodulin-
induced phosphorylation of
the transcription factor for IL-
2.
Nephrotoxicity, neurotoxicity,
hypertension, lymphoproliferative
disorders, other malignancies,
post-transplant diabetes mellitus,
viral infections, hirsutism and
gingival hyperplasia.
Tacrolimus,
FK506
Binds to FKBP-12. FK506-FKB-
12 complex blocks calcineurin-
calmodulin-induced
phosphorylation of the
transcription factor for IL-2.
Mechanism is identical with
CsA.
Nephrotoxicity, neurotoxicity,
glucose homeostasis related
problems, hypertension,
lymphoproliferative disorders,
other malignancies, post-
transplant diabetes mellitus, viral
infections, alopecia and pruritus.
Insomnia, headache, tremor,
muscle pain, fatigue and GI-
symptoms are listed as less
frequent side effects.
Mycophenolate
mofetil,
MMF
MMF is converted to MPA, a
inhibitor of IMP-
dehydrogenase, a key enzyme
in "de novo" pathway of
purine synthesis. The anti-
proliferative action is mainly
directed to lymphocytes, as
they are highly dependent on
this pathway.
Diarrhea, vomiting and
opportunistic infections.
Lymphoproliferative disease in
approximately 1 %.
Rapamycin,
Sirolimus,
RPM
RPM binds to FKBP
immunophilins, but has no
affinity for the calcineurin-
calmodulin complex. RPM
blocks the 2nd set of
phosphorylation in the late GI
phase of the cell cycle.
Hypertriglyceridemia,
hypercholesterolemia, leukopenia,
thrombocytopenia, elevated liver
enzymes and hypokalemia. Viral
infections.
Steroids 1. anti-inflammatory:
inhibition of phospholipase A2
and thereby arachidonic acid
cascade (cyclo-oxygenase,
thromboxane, prostacyclin)
and 5-lipoxynase pathway.
2. inhibits APC function and
transcription of several
cytokines.
Poor wound healing ,
osteoporosis, avascular necrosis,
cataracts, iatrogenic diabetes
mellitus, obesity and
hypertension. Cushingoid
appearance and growth
retardation in children.
Azathioprine Anti-proliferative action.
Blocks conversion of IMP to
AMP and GMP, inhibition of
PRPP amidinotransferase
Side effects from all rapidly
dividing tissues, particularly bone
marrow. Hepatotoxic. Potentially
mutagenic.
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2. The effect of vitamin D analogs on malignant cells
2.1 Induction of differentiation and inhibition of cell growth
AML cells are unable to differentiate to functional mature cells. The maturation
of the cells is blocked at an early stage and the cells remain in a rapidly
dividing proliferative pool. This arrest is caused by chromosomal alterations
that affect transcription of genes involved in myeloid differentiation.
The maturation arrest of AML cells can be reversed in experimental models as
demonstrated by Sachs and colleagues (Fibach et al., 1972; Sachs, 1978).  In
these experiments it was shown that myeloid leukemic cells can be
differentiated to mature granulocytes and macrophages by
macrophage/granulocyte inducer type 2, i.e. interleukin 6 (IL-6) (reviewed in
(Sachs, 1990; Sachs, 1987)). Further success was obtained with IL-1, D-factor
(also called HILDA and leukemia-inhibitory factor) (Sachs, 1995), retinoic acid
(RA) (Breitman et al., 1980), tumor necrosis factor (TNF) (Peetre et al., 1986) and
vitamin D3  (Honma et al., 1983; Miyaura et al., 1981). The various results
obtained in these experiments suggested that these differentiation inducers act
by different mechanisms, and there are multiple differentiation pathways
sharing common final stage/stages.
Most research thereafter has concentrated on all-trans retinoic acid and vitamin
D3. All-trans retinoic acid induces differentiation of several human leukemic
cell lines and acute promyelocytic leukemia (APL) cells (Breitman et al., 1980;
Castaigne et al., 1990; Chen et al., 1991; Huang et al., 1988). The physiologically
active form of vitamin D3 is 1α25(OH)2D3. It induces some myeloid leukemia
lines to differentiate along the monocyte/macrophage pathway and prolongs
the survival time of leukemic mice (Abe et al., 1981; Miyaura et al., 1981; Zhou
et al., 1990). The biologic effects of RA and VD3 are mediated by their nuclear
receptors, retinoic acid receptor (RAR), retinoid X receptor (RXR), and vitamin
D3 receptor (VDR) (Evans, 1988). They are members of the steroid receptor
superfamily and act as ligand-inducible transcription factors by binding to
their cognate responsive DNA elements, known as RA-responsive element
(RARE) and vitamin D3-responsive element (VDRE) (Baker et al., 1988;
Petkovich et al., 1987). RAR and VDR form heterodimers with RXR to bind
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DNA with high affinity and effect transcriptional activation of target genes
(Bugge et al., 1992; Kliewer et al., 1992; Yu et al., 1991).
Inhibition of the G1/S transition in the cell cycle induces differentiation and
growth arrest of both HL-60 and U937 cells (Jiang et al., 1994; Schwaller et al.,
1995). The p21WAF1/CIP1 protein is a cyclin-dependent kinase (cdk) inhibitor that
is one of the regulators of cell cycle progression in the G1/S transition.
Incubation of HL-60 cells with 1α25(OH)2D3 causes transient overexpression of
p21WAF1/CIP1 (Schwaller et al., 1995).  p21WAF1/CIP1promoter contains a VDRE, and
exposure of U937 myelomonoblasts to 1α25(OH)2D3  results in transcriptional
activation of p21WAF1/CIP1, probably through a ligand/VDR/VDRE interaction
(Liu et al., 1996). There is also strong evidence that p27KIP1 protein blocks entry
to the S phase of cell cycle in 1α25(OH)2D3  treated HL-60 cells (Muto et al.,
1999; Wang et al., 1996). Recently it was shown that a novel analog, Gemini-19-
nor increased in HL-60 both the proportion of cells in the G(1)/G(0) phase and
expression level of p27kip1. Gemini-19-nor also stimulated expression of the
potential tumor suppressor, PTEN. Furthermore, other inducers of
differentiation, all-trans-retinoic acid and 12-O-tetradecanoylphorbol 13-
acetate, increased PTEN expression in HL-60 cells. PTEN expression appeared
to parallel terminal differentiation of myeloid cells (Hisatake et al., 2001). The
end effect appears similar to results obtained with p21WAF1/CIP1 above.
In addition to studies on leukemic cells there has been a great number of
promising studies utilizing VD3 or the novel analogs on other malignant cells
(Shany et al., 2001). These include breast (Brenner et al., 1995; Chaudhry et al.,
2001; James et al., 1994; James et al., 1998; Saunders et al., 1995; Yang et al.,
2001), prostate (Peehl et al., 1994; Skowronski et al., 1995), colon (Diaz et al.,
2000; Shabahang et al., 1994; Wali et al., 1995), squamous skin (Akutsu et al.,
2001; Yu et al., 1995), and glioma cells (Naveilhan et al., 1994).
In summary, recent studies suggest that the ability of VD3 and its novel analogs
to induce differentiation and to inhibit growth of various malignant cells, is
initiated through the activation or repression of target genes by VDR, and
mediated through an increased expression of several cdk inhibitors.
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2.2 Vitamin D analogs and apoptosis
Apoptosis is a Greek word meaning "to fall away from". It was chosen as it
describes the microscopic membrane bound cell fragments, apoptotic bodies,
resulting from programmed cell death. Apoptosis plays an important role in a
variety of physiological processes. Defects in the regulation of apoptosis
contribute to the course of many diseases.  Cancer and autoimmune diseases
where there is too little apoptosis and probably stroke and Alzheimer's disease
when there is too much (Reed, 2000).
Apoptosis is caused by activation of a family of intracellular cysteine proteases
which cleave their substrates at aspartic acid residues, known as caspases for
cysteine aspartyl specific proteases (Alnemri et al., 1996). Many caspases are
involved in apoptosis, a few are not. A subgroup of caspases: caspase 1, 4 and 5
process pro-inflammatory cytokines pro-IL-1β  and pro-IL-18. The proteases
match the cleavage sites within these pro-cytokines but not the cleavage sites of
the proteins known to undergo cleavage during apoptosis (Reed, 1999;
Salvesen and Dixit, 1997).
Two pathways for caspase activation have been described in detail: the death
receptor or extrinsic pathway and the intrinsic pathway (Figure 1). In the
extrinsic pathway, ligand binds to TNF-family receptor, such as TNFR1 and
FAS. These receptors recruit adapter proteins to their cytosolic death domains
(DD), which then bind death effector domain (DED)-containing pro-caspases,
especially pro-caspase-8. This becomes caspase-8 which is shown to directly
cleave and activate the effector protease, caspase-3 (Salvesen and Dixit, 1997;
Wallach et al., 1999; Yuan, 1997). In contrast, intrinsic pathway involves
mitochondria, which release cytochrome c into the cytosol triggered by various
stimuli, including elevations in the levels of pro-apoptotic Bcl-2 family proteins
such as Bax.  In the cytosol cytochrome c binds and activates Apaf-1, which
then binds and activates pro-caspase-9. Active caspase-9 activates caspase-3
similarly to caspase-8 in the extrinsic pathway (Green and Reed, 1998; Reed,
2000).
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Figure 1. Extrinsic (left) and intrinsic (right) pathways for caspase activation.
The extrinsic pathway can be initiated by members of the TNF family of cytokine
receptors, such as TNFR1 and Fas. These proteins recruit adapter proteins to their
cytosolic death domains (DD), including Fadd, which then binds death effector
domains (DED) containing pro-caspases, particularly pro-caspase-8. The intrinsic
pathway can be initiated by release of cytochrome c from mitochondria. Induced by
various stimuli, including elevations in the levels of pro-apoptotic Bcl-2 family
proteins, such as Bax. In the cytosol, cytochrome c activates Apaf-1, allowing it to bind
and activate pro-caspase-9. Active caspase-9 (intrinsic) and caspase-8 (extrinsic) have
been shown to directly cleave and activate the effector protease, caspase-3.
Numerous findings suggest the Bcl-2 family of proteins to be one of the key
elements in deciding the fate of the cell. The anti-apoptotic Bcl-2 gene is
activated by chromosomal translocations in the majority of non-Hodgkin's
lymphomas (Tsujimoto et al., 1985) and is also overexpressed in many solid
tumors (Reed et al., 1996). On the other hand, loss of function mutations have
been identified in the pro-apoptotic Bax genes in many tumors. Analysis of
Bax-knockout mice indicates that Bax is a tumor suppressor in vivo (Yin et al.,
1997). These mice interestingly displayed a marked resistance to neuronal cell
death induced by ischemia, axotomy and other insults. Bax is also increased in
apoptosing neurons in Alzheimer's disease. Transcription of Bax is also
indirectly regulated by p53, providing yet another connection in this complex
pathway. In humans, 20 members of the Bcl-2 gene family have been described
to date. These genes code the antiapoptotic proteins: Bcl-2, Bcl-XL, Mcl-1, Bfl-1
(A1), Bcl-W and Boo (Diva) and pro-apoptotic proteins: Bax, Bak, Bok (Mtd),
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Bad, Bid, Bim, Bik, Hrk, Bcl-XS, APR (Noxa), p193, Bcl-G, Nip3, and Nix (BNIP)
reviewed by Reed (2000). Some of these proteins are even products of the same
gene through alternative mRNA splicing producing opposing end results on
apoptosis (Bcl-XL and Bcl-XS).
Vitamin D3 analogs induce apoptosis in many malignant cell types: leukemia
(Elstner et al., 1996; Hisatake et al., 2001), myeloma (Park et al., 2000), breast
cancer (Colston et al., 1992; James et al., 1998; Sundaram et al., 2000), prostatic
cancer (Fife et al., 1997), colon cancer (Diaz et al., 2000; Evans et al., 1999),
melanoma (Danielsson et al., 1998), glioma (Baudet et al., 1996), and cutaneus
malignancies (Hershberger et al., 1999; Majewski et al., 2000). It remains still
unknown how vitamin D3 analogs induce apoptosis. Early reports stated that
the VD3 analogs induced apoptosis of myeloid leukemia cells while
simultaneously down-regulating the expression of Bcl-2 protein suggesting an
association between these two events.  However, Grillier then reported that a
VD3 analog could induce apoptosis in a HL-60 variant without reduction in the
cellular levels of Bcl-2 (Grillier et al., 1997).
On the other hand, a slight elevation in the levels of the pro-apoptotic Bax
protein by vitamin D analogs has also been reported (Elstner et al., 1996). This
slight elevation may be significant as apoptosis depends on the balance of
antiapoptotic and pro-apoptotic factors. The former include the antiapoptotic
members of the Bcl-2 family of proteins Bcl-2 and Bcl-XL and the latter Bax and
Bcl-XS (Reed, 1998; Yang and Korsmeyer, 1996).
Interestingly, Mathiasen et al. reported that VD3 analogs induced apoptosis via
a novel caspase- and p53-independent pathway in MCF-7 and T47D human
breast cancer cell lines. MCF-7 cells express a wild-type p53 tumor suppressor
protein, while T47D cells lack a functional p53. In their experiments, VD3
analogs induced growth arrest followed by apoptosis in both cell lines.
Inhibition of caspase activation by several methods showed no effect on the
induction of growth arrest or apoptosis by the VD3 analogs under conditions in
which apoptosis induced by TNF or staurosporine was effectively inhibited.
Neither caspase-3-like protease activity nor cleavage of caspase substrate
poly(ADP)ribose polymerase was detected in lysates from apoptotic cells
following the successful VD3 analog treatment. The VD3-induced apoptosis
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could be inhibited by a forced overexpression of Bcl-2 protein (Mathiasen et al.,
1999).
Taken together, these findings suggest that the VD3 analogs may use several
pathways to induce apoptosis. However, the full understanding of the precise
mechanism requires still further studies.
3. Vitamin D analogs in immunosuppression
3.1 Background
The role of 1α25(OH)2D3 in mineral and bone metabolism has been recognized
and well characterized for a relatively long time (Norman et al., 1982). In the
early 1980s several investigators described VD3 receptors in many tissues not
regarded to participate in mineral metabolism (Bhalla et al., 1983; Colston et al.,
1981; Eisman et al., 1979; Feldman et al., 1980; Tanaka et al., 1982). This led to
the conclusion that this hormone might have a broader function than
previously appreciated.
Studies for immunoregulatory properties of vitamin D started. Tsoukas et al.
demonstrated that 1α25(OH)2D3 suppressed the production of interleukin-2 (IL-
2) and inhibited the proliferation of phytohemagglutin (PHA) stimulated
lymphocytes (Tsoukas et al., 1984). Very soon thereafter Bhalla et al. reported
similar results with antigen-induced T cell activation (Bhalla et al., 1984).
Provvedini et al. found a nuclear VD3 receptor in human B-lymphocytes. This
was significant, as previous studies had described the receptor in the cytosol. In
the same study they also demonstrated that VD3 inhibited immunoglobulin (Ig)
production of Epstein-Barr virus infected B-lymphocytes (Provvedini et al.,
1986). A year later Reichel et al. demonstrated inhibition of γ-interferon
synthesis by peripheral blood lymphocytes, using 1α25(OH)2D3 (Reichel et al.,
1987). This inhibitive effect was shown to be independent of the levels of IL-2.
A real breakthrough in VD3 immunosuppression came with the development
of novel analogs. In 1991 Binderup et al. reported of the new 20-epi-vitamin D3
analogs. These new molecules were exceptionally effective in inhibiting cell
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proliferation and inducing differentiation but also in inhibiting T-cell activation
in vitro. Many of these novel analogs were several orders of magnitude more
active than CsA (Binderup et al., 1991). Literally hundreds of new analogs have
been screened by various investigators globally, but only a few have shown
real promise (Bertolini et al., 1999; van Etten et al., 2001).
3.2 Prevention of rejection
After encouraging results in vitro and in experimental autoimmune animal
model, VD3 analogs were further studied in solid organ transplantation. In 1991
Lemire et al. succeeded in prolonging the survival of murine cardiac allografts
from 11 days to 27 days by the VD3 analog 1,25(OH)2-∆16-cholecalciferol
(Lemire et al., 1992).
In 1993 Veyron et al. prolonged skin allograft survival time in mice. The results
were obtained with 1α25(OH)2D3 , two different analogs CB966 and KH1060 as
monotherapy or in combination with CsA. In the study, KH1060 was the most
active compound, but the combination with CsA was able to prolong
significantly graft survival more effectively than the use of either agent alone
(Veyron et al., 1993).
A new 20-epi-vitamin D3 analog, MC1288 was reported to be over 7000 times
more potent in a mouse thymocyte costimulatory assay than 1α25(OH)2D3 , and
300 times more potent in inhibiting allogeneic T-cell activation in a mixed
lymphocyte culture (Binderup et al., 1991). Johnsson and Tufvesson studied
this analog in heterotopic cardiac allograft model, heterotopic small bowel
transplantation model, and in graft-versus-host reaction after small bowel
transplantation.  MC1288 significantly prolonged heart graft survival time in
the study. It was also tested along with the immunostimulator LS-2616
(linomide), which totally abrogates the immunosuppressive effect of CsA. The
survival time in the MC1288 treated group was halved by LS-2616, but clearly
demonstrated that CsA and MC1288 exert their effects at least partly via a
different mechanism. In small bowel transplantation the amount of hyaluronic
acid secreted in the intestinal lumen was reduced thus indicating better graft
function (Johnsson and Tufveson, 1994).
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3.3 Prevention of GVHD
To our knowledge, there is only one study so far studying GVHD and the
effects of vitamin D analogs. Johnsson and Tufveson studied the effects of
MC1288 on graft-versus-host reaction after small bowel transplantation
(Johnsson and Tufveson, 1994). In the untreated group signs of GVHD
appeared around day 7, with progressive disease until death around day 14.
Median in MC1288 group was 9,5 days (range 7-14). The two rats surviving for
14 days developed visible signs of GVHD later than the untreated, while the
rest died without signs of GVHD. The authors concluded that the treatment
had no beneficial effect on GVHD.
3.4 Prevention of autoimmune diseases
Effect of vitamin D analogs has been studied in several autoimmune disease
models. Murine experimental autoimmune encephalomyelitis (EAE) is a
primary T-cell mediated model of autoimmunity that is used as a model for
multiple sclerosis. EAE can be easily induced in susceptible mice with central
nervous tissue extracts. Within two weeks the animals develop acute paralysis
with central nervous system inflammation (Paterson, 1976).  Lemire and Archer
managed to prevent the disease with the combination of 1α25(OH)2D3 and low
calcium diet (Lemire and Archer, 1991). 1α25(OH)2D3  remarkably inhibited the
induction of the disease, antibody production and development of histologic
lesions.
Lemire et al. demonstrated the beneficial effect of VD3 in the prevention of the
histological signs of systemic lupus erythematosus (SLE) in an experimental
murine lupus model. In this model MRL/l mice spontaneously develop
lymphoid hyperplasia, dermatitis, vasculitis, arthritis, myocardial infarcts, and
glomerulonephritis (Lemire et al., 1992).
Lillevang et al. experimented with the novel VD3 analog KH1060 on mercuric-
chloride-induced autoimmune rat model. This model is characterized by
polyclonal activation of B-lymphocytes, proliferation of autoreactive CD4+ T-
cells, and very high serum levels of IgE. Autoantibodies to the components of
glomerular basement membrane such as laminin, type IV collagen and
fibronectin lead to the development of glomerulonephritis resulting in severe
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proteinuria, the most prominent feature of this model. While KH1060 as
monotherapy was effective in this study, both KH1060 and CsA prevented the
autoimmune reaction in a dose-dependent manner and their effects were found
to be additive (Lillevang et al., 1992).
More recently Casteels et al. managed to prevent the recurrence of type 1
diabetes in syngeneic islet grafts in nonobese diabetic mice with the VD analog
KH1060, both alone and in combination with CsA (Casteels et al., 1998). Van
Etten et al. later demonstrated in a similar model that the combination of VD3
analog TX527 with CyA and with IFNβ prolonged syngeneic graft survival
significantly (van Etten et al., 2001).
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AIMS OF THE STUDY
The aim of this study was:
1. To investigate the effects of vitamin D3 analogs on the differentiation and
growth of leukemia cells in vitro, and combinations of VD3 analogs with
chemotherapy in vitro.
2.  To investigate VD3 in the prevention of acute and chronic rejection in solid
organ transplant model, and graft-versus-host disease in BMT model in vivo in
rats.
METHODS
5.1 Materials
Cells (I, II)
The HL-60 cells are a cell line originally derived from a patient with acute
myeloid leukemia (Collins, 1987; Collins et al., 1977). These cells have a
capability to differentiate.
Bone marrow cells from AML patients were obtained from routine samples
after informed consent according to institutional guidelines. Mononuclear cells
were isolated by Ficoll-Hypaque density gradient and suspended in Iscove's
modified Dulbecco's medium (IMDM; Sigma Diagnostics, St.Louis, MO, USA)
with 10% fetal calf serum (FCS; Bioclear, Wilts, UK). Standard karyotype
analysis on bone marrow cells was performed by G-banding technique.
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Vitamin D analogs (I, II, III, IV)
The following compounds were used in this study:
- 1(S), 3(R)-Dihydroxy-20(R)-(1(S)-1-ethoxy-5-ethyl-5-hydroxy-2-heptyn-1-
yl)-9,10-seco-pregna-5 (Z), 7(E), 10(19)-triene (CB1093),
- 24a, 26a, 27a-tri-homo-22, 24-diene-1-alfa, 25-(OH)2-D3 (EB1089),
- 20-epi 1,25(OH)2D3 (MC1288), and
- 1α25(OH)2D3 (Figure 2).
All compounds were synthesized at the Department of Chemical Research, Leo
Pharmaceutical Products, Ballerup, Denmark. The compounds were supplied
as solutions in isopropanol (4 x 10-3M) and stored at -200C. For in vitro use, the
analogs were diluted to IMDM (Sigma Diagnostics). For in vivo use, the
analogs were diluted to phosphate buffered saline (PBS) with 0.02% rat
albumin.
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Experimental animals (III, IV)
Inbred rat strains DA, WF, BN and LEW were purchased from the Laboratory
Animal Center, University of Helsinki, Helsinki. They received humane care in
compliance with the Principles of Laboratory Animal Care and the Guide for
the Care and Use of Laboratory Animals prepared and formulated by the
National Institute of Health (NIH Publication no. 86-23, revised 1985). Pellets
(Altromin Nr. 1314, Standard diet, Chr. Petersen A/S, Ringsted, Denmark)
were used as basic diet and tap water was given ad libitum.
5.2 In vitro experiments
Cell proliferation by methylcellulose colony forming assay (I, II)
2x103 HL-60 cells in exponential growth phase from liquid culture or 1x105
AML cells were plated in 25 mm petri dishes (Nunc; Roskilde, Denmark) and
cultured for 10 days. Cells were mixed in methyl cellulose (Fluka; Buchs,
Switzerland), 1 ml containing 0.05 ml of 20%, BSA (Sigma), 1 µl of 2-mercapto-
ethanol (Fluka), 0.2 ml of FCS (Bioclear), 0.165 ml of IMDM, and 0.1 ml of
supernatant from human bladder cancer cell line 5637 grown as continuous
culture in IMDM.
30 µl of different concentrations of vitamin D analogs were placed on the
bottom of each dish. The total volume was 300 µl/well. Number of colonies
(>40 cells/colony) was counted under inverted microscope. All experiments
were done in triplicate with various concentrations of EB1089, CB1093 or
idarubicin (IDA) (Pharmacia & Upjohn, North Peapack, NJ) and controls with
no vitamin D analog or IDA added. Experiments with HL-60 cells were
repeated at least three times.
Cell proliferation by 3H-thymidine incorporation (I)
The cell solutions (grown in suspension culture flasks for a week with various
concentrations of vitamin D analogs) were placed on 96 micro well tissue
culture plates (Nunc), each well containing 2X105 cells and 20 µl of 100 µCi 3H-
thymidine. Total volume in each well was 200 µl. The plates were harvested
after 12-hour incubation at 370C using a Skatron Combi Cell Harvester. After
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the samples were dried, 1 ml of OptiScint "HiSafe" (Fisons Chemicals,
Loughborough, Leics, UK) was added to each test tube. Scintillation counts
were measured with a beta counter (Rackbeta Liquid Scintillation Counter,
LKB Wallac, Turku, Finland). Proliferation of cells was determined as
percentages of controls.
Liquid culture and differentiation assays (I)
HL-60 cells differentiate towards macrophage-like cells when cultured in the
presence of 1α25(OH)2D3. This differentiation can be measured by
alpha-naphtyl acetate esterase (ANAE) activity in the cells and by their ability
to reduce nitroblue tetrazolium (NBT). HL-60 cells were grown in suspension
culture flasks (T-25, Falcon) containing IMDM and 10% FCS and different
concentrations of different vitamin D analogs in humidified atmosphere with
5% CO2 at 37
0C. Total volume in each flask was 5 ml. Cells were harvested after
7 days in culture. Induction of differentiation of HL-60 cells was measured both
by reduction of NBT and by ANAE staining. For NBT, cell suspensions (2x105
cells/ml) were mixed with an equal volume of NBT solution containing 1,7 g of
bovine serum albumin (BSA), 125 mg of NBT and 100 µ g
12-0-tetradecanoylphorbol-13-acetatein in 100 ml of IMDM. The suspension
was incubated for 30 min at 370C. Cells were washed twice in cold PBS,
cytocentrifuged, fixed in methanol for 5 min and stained with Gram safranin
for 10 min. Alpha-naphtyl acetate esterase kit (Sigma) was used for ANAE
stainings, which were done according to the manufacturer's guidelines. All
experiments were done at least three times with controls having no  VD3 analog
added in cultures.
Mixed lymphocyte cultures (III)
To obtain rat lymphocytes WF rats were stimulated for 24 h by intravenous
injection of 10 x 106 DA-strain spleen cells. Spleen cells were collected and then
incubated overnight. Cells that were used for stimulation were irradiated. 2x106
stimulator (DA) and 106 responder (WF) cells were incubated with various
concentrations ( 10-6M-10-11M) of VD3 analogs in 96 micro well tissue culture
plates (Nunc). The following controls without vitamin D3 analogues were used:
irradiated stimulator cells, irradiated stimulator cells mixed with nonirradiated
stimulator cells, and irradiated stimulator cells mixed with responder cells.
After an incubation period of five days, 20 µl of 100 µCi 3H-thymidine was
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added to each well and the activity was measured with beta counter (Rackbeta
Liquid Scintillation Counter). Proliferation of cells was determined as
percentages of nontreated controls in four independent experimental sets.
Analysis of apoptosis (II)
20x106 HL-60 cells were incubated in suspension culture flasks (T-25, Falcon,
Becton Dickinson Labware, Franklin Lakes, NJ) containing IMDM, 10% FCS
and different concentrations of EB1089 and CB1093 in humidified atmosphere
with 5% C02 at 37
0C. Total volume in each flask was 5 ml.
After 72 hour incubation the contents of each flask were divided to five flasks, 4
ml of IMDM and IDA was added in concentrations from 10-9 M to 10-12 M and
one flask with no IDA in each set of five. Resulting 25 flasks were incubated for
48 hours. Percentage of apoptotic, live and dead cells was evaluated using a
commercial kit, Apoptosis Detection Kit (R & D Systems, Minneapolis, MN),
according to manufacturer's instructions. Thereafter, the samples were
immediately analyzed with flow cytometry (FACS IV, Becton Dickinson). The
results are expressed as the percentage of live, necrotic and apoptotic cells, as
counted with flow cytometry.
5.3 In vivo experiments
In vivo experiments on blood calcium levels (I)
Inbred DA (AG-B4, RTla) rats were divided in the following groups, each
containing three rats: CB1093 0.1 ug/kg, CB1093 0.3 ug/kg, CB1093 1.0 ug/kg,
1α25(OH)2D3 0.1 ug/kg, 1α25(OH)2D3 0.3 ug/kg, 1α25(OH)2D3 1.0 ug/kg. The
treatment was administered intraperitoneally every other day. Serum calcium
was measured by enzyme-linked immunosorbent assay (ELISA) from
peripheral blood samples taken every seven days. The animals were sacrificed
after five weeks.
Aortic transplantations (III)
Allogeneic transplants were performed from DA to WF strain. Rats weighing
250-350 grams and of 2 to 4 months of age were used as donors and recipients.
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A segment of the descending thoracic aorta, approximately 3 cm in length, was
excised, perfused with PBS and used as a transplant (Mennander et al., 1991).
The rats were anesthetized with chloral hydrate, 240 mg/kg i.p., and 0.3
mg/kg s.c. buprenorphine (Temgesic, Reckitt & Colman, Hull, England) was
used for post-operative pain relief.  The graft was transplanted into a
heterotopic position below renal arteries and above bifurcation in the
abdominal cavity.  The grafts were removed at 1 or 3 months
posttransplantation, and processed for histology and frozen sections.
Vitamin D analogue, MC1288 (Leo Pharmaceutical Products) was given in
three different doses: 0.1 µg/kg/every second day (esd) ip, 0.05 µg/kg/esd,
and 0.01 µg/kg/esd. Cyclosporine A (CsA; Sandimmun Neoral, Sandoz, Basel,
Switzerland) 5 mg/kg/d po, was used as a standard drug either alone or in
combination with MC1288. The CsA levels were monitored weekly from
peripheral blood samples using a radioimmunoassay kit for CsA (CYCLO-Trac,
Incstar Corporation, Stillwater, Minnesota, USA).
Bone marrow transplantation (IV)
Allogeneic bone marrow transplantations were performed using adult Brown
Norway (BN; RT1l) rats as recipients and 10-week-old Lewis (LEW; RT1n) rats
as bone marrow cell donors. The cells were collected by flushing the femurs
with saline. The recipient animals were irradiated with 960 rad (Varian Climac
600c, 6 MV photon irradiation, distance 120 cm, field size 40 x 40 cm2) prior to
BMT. After 24 hours, 60-80x10
6
 mononuclear bone marrow cells from LEW rats
were injected into BN recipients.
The animals were divided into four groups with the following treatments:
1) vitamin D analog MC1288 (Leo Pharmaceutical Products) 0.1 µg/kg/esd i.p.
2) CsA (Neoral; Novartis) 5 mg/kg/d, p.o.
3) MC1288 0.1 µg/kg/esd and CsA 5 mg/kg/d together
4) a control group receiving no immunosuppressive treatment.
CsA, which is used as a standard treatment in BMT patients, provided a
secondary control group. Sulfonamide and trimethoprim (Cotrim; Merckle,
Blaubeuren, Germany) was administered for ten days i.p. as infection
prophylaxis to all recipients.
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Histological analysis (III, IV)
(III) To study histological manifestations in the aortic allografts, the animals
were sacrificed at 1 and 3 months post transplantation. Cross sections were
stained with Mayer´s hematoxylin and eosin and prepared for quantitation of
morphological changes in the graft. The changes were quantitated according
to standard morphometric principles (Aherne and Dunnill, 1982) and
expressed as point score units (psu), i.e., mean number of points falling over a
given anatomical area using straight cross-sectional lines and a 0.02 mm grid.
The number of nuclei in adventitia, media and intima and the thickness of
intimal lesion, separated from each other by intimal and external elastic
laminae were evaluated.
(IV) To study histological manifestations of GVHD, the animals were sacrificed
20 days after transplantation. After BMT from Lewis to BN rat strain, the
strongest histological changes are observed in the liver, a model parenchymal
target organ for acute GVHD in this strain combination (Renkonen and Häyry,
1984). Biopsies were taken from skin, liver and spleen, fixed in 4% formaline
solution and processed for histology. Paraffin sections were stained with
Mayer´s hematoxylin and eosin.
Histologic features of acute GVHD were graded independently by two
investigators (I. Pakkala & E. Taskinen) on a 0 to 4 scale using previously
published grading systems (Lerner et al., 1974; Renkonen and Häyry, 1984; Sale
et al., 1977; Slavin and Santos, 1973). Briefly, skin manifestations were graded
for their focal or diffuse vacuolar degeneration of epidermal basal cells (grade
1), diffuse spongiosis and dyskeratosis or eosinophilic degeneration of
epidermal cells (grade 2). In grade 3 there were all above changes and partial
separation of the dermal-epidermal junction, and in grade 4 loss of epidermis
was seen. Liver manifestations were graded for small lymphocyte and plasma
cell infiltration into the portal tracts, voluminous Kupffer cells, portal and/or
central venous endothelialitis and evidence of bile duct injury or cholangitis.
Spleen manifestations were graded for fibrosis and hypocellularity with an
increase in siderophages and megakaryocytes. The results were expressed as
the mean total increment (MTI) for each of the organs and summarized
resulting in a maximum score of 12 reflecting the severity of acute GVHD.
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Immunoperoxidase stainings (III)
For immunohistochemistry, 3-4 µm thick frozen sections were stained by an
immunoperoxidase technique using monoclonal anti-rat antibodies to
interleukin-2 receptor α-chain (CD25) (IL-2R; clone OX-39, PharMingen, San
Diego, CA), to T helper cells (CD4; clone W3/25, Seralab, Sussex, UK), to
cytotoxic T cells (CD8; clone OX8, Seralab), and to macrophages (ED1; Sero-
Tec, UK). The cryosections were fixed with chloroform for 30 min, and then
stained using standard 2-layer indirect immunoperoxidase technique. Intensity
of the staining was evaluated using an arbitrary scale scored from 0 to 3 where
0 indicates no staining and 3 very strong staining.
(IV) Serial frozen sections were immunostained using a standard multi-layer
method. Briefly, after acetone and chloroform fixation of the slides the
nonspecific staining was blocked with appropriate 1.5% nonimmune serum
(Vector Laboratories, Burlingame, CA). Primary  antibodies are listed after their
respective targets as follows CD4 (W3/25; Harlan Sera-Lab Ltd, Belton,
England), CD8 (OX8; Sera-Lab), MHC class II common determinant (OX6; Sera-
Lab), nitrate oxide synthase 2 (NOS2) (M-19; Santa Cruz Biotechnology, Santa
Cruz, CA), and NKR-P1A (10/78; PharMingen, San Diego, CA). Secondary
antibody was biotinylated and was followed by avidin-biotin complex
(Vectastain Elite ABC Kit, Vector Laboratories) and chromogen 3-amino-9-
ethylcarbazole (AEC; Sigma, St. Louis, USA) containing 0.4% hydrogen
peroxidase, yielding a brown-red reaction product. The specimens were
counterstained with hematoxylin.
Immunostaining was evaluated by two observers and results were expressed
as mean number of positive cells/visual field at magnification 1000x.
In vivo proliferation assay by bromodeoxyuridine (BrdU)
(III) The rats received 300 µl of bromodeoxyuridine (BrdU, Zymed
Laboratories) by i.v. injection 4 hours before sacrifice. Frozen sections of aortic
allografts were used for immunoperoxidase staining by BrdU primary
antibody.  First, the sections were digested with 0.1% pepsin in 0.1 M HCl for
30 min.  Thereafter they were fixed in 95% volume percent of formamide in
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0.15 M tri-sodium-citrate in +70°C for 45 min, and washed three times with
PBS.  Blocking of unspecific staining was performed using horse serum for 30
min.  The primary antibody for BrdU (Mouse anti-bromodeoxyuridine, Bu20a,
Dako Immunoglobulins A/S, Glostrup, Denmark) was used at a dilution of
1:20; thereafter Vectastain ABC-kit (Vectastain ABC-kit Elite PK-6102, mouse
IgG, Vector Laboratories Inc., Burlingram, CA) was used according to
manufacturer's instructions. The frozen sections were counterstained and
scored as labeled cells/cross section.
5.4 Statistical methods
(I, II, IV) Statistical analysis was performed using the non-parametric Kruskall-
Wallis test with Dunn correction for multiple comparisons, where p<0.05 was
considered significant.
(III) The nonparametric Mann-Whitney U test was used in comparison of two
groups and Kruskall-Wallis test with Dunn correction for multiple
nonparametric groups.
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RESULTS
6.1 CB1093, a novel vitamin D analog; effects on differentiation and clonal
growth on HL-60 and de novo leukemia cells (I)
The effects of vitamin D analogs on differentiation of HL-60 cells
All three analogs demonstrated a dose dependent effect on HL-60 cells. ANAE
stainings showed CB1093 to be 3.5 times more potent than EB1089 and 45 times
more potent than 1α25(OH)2D3 in the induction of esterase (ED50 2x10
-9, 7x10-9,
and 9x10-8, respectively). The reduction of nitroblue tetrazolium (NBT)
correlates with the induction of superoxide production of differentiated HL-60
cells. Here we showed that CB1093 reduced NBT 50 times more efficiently than
EB1089 and 30 times more efficiently than 1α25(OH)2D3 (ED50 1x10
-9, 5x10-8, and
3x10-8, respectively).
The effect of vitamin D analogs on proliferation of HL-60 cells
In methyl cellulose colony assays CB1093 was 7 times more efficient than
EB1089 and 10 times more efficient than 1α25(OH)2D3 in inhibiting
proliferation (ED50 9x10
-11, 6x10-10, 9x10-10, respectively). The proliferation of HL-
60 cells measured by 3H-thymidine incorporation showed CB1093 to be 3 times
more potent in inhibiting cell proliferation than EB1089, and 20 times more
potent than 1α25(OH)2D3 (ED50 3x10
-9, 9x10-9 and 6x10-8, respectively).
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Table 2. Relative efficacies of selected vitamin D analogs as compared to 1α25(OH)2D3
Relative efficacy
Analog ANAE NBT Inhibition of clonal growth
1α25(OH)2D3 1 1 1
CB 1093 450 300 100
EB1089 12.9 0.6 1.5
*1,25(OH)2-16ene-23yne-D3 120 20 1.8
Relative efficacy is calculated by:
concentration of analog
to elevate serum Ca++
               X
ED50 of 1α25(OH)2D3 in ANAE,
NBT or colony assay experiments
concentration of 1α25(OH)2D3
to elevate serum Ca++
ED50 of analog in ANAE, NBT
or colony assay experiments
Abbreviations: NBT, nitroblue tetrazolium; ANAE, alpha-naphtyl acetate esterase;
ED50 represents the effective dose achieving 50% response.
*As reported in (Zhou et al., 1989)
The effect of vitamin D analogs on de novo leukemia cells
CB1093 was even more effective against de novo AML cells under similar
conditions. In methyl cellulose colony assays CB1093 was 25 times more
efficient than EB1089 and about 100 times more efficient than 1α25(OH)2D3 in
inhibiting the proliferation of AML cells (ED50 5x10
-11, 8x10-10 and 6x10-9,
respectively).
Effect on blood calcium
1α25(OH)2D3 and EB 1089 have been shown to have similar calcemic effects
(Pakkala et al., 1995). CB1093 had a much lesser effect on calcium metabolism
than 1α25(OH)2D3 when given intraperitoneally. The changes in S-Ca values for
the groups receiving high, medium and low i.p. doses (1.0 ug/kg, 0.3 ug/kg
and 0.1 ug/kg) of CB1093 were 2.50-2.63 mmol/l, 2.48-2.50 mmol/l and 2.52-
2.33 mmol/l, respectively. Thus, CB1093 did not cause hypercalcemia with the
doses used in this study.
The groups receiving high and medium doses (1.0 ug/kg and 0.3 ug/kg) of
1α25(OH)2D3 developed hypercalcemia during the experiment (S-Ca: 2.51-2.92
mmol/l and 2.50-2.71 mmol/l, respectively). In the group receiving 0.1 ug/kg
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of 1α25(OH)2D3 , S-Ca rose only from 2.50 to 2.62 mmol/l. Our preliminary
results with short oral administration suggest that CB1093 has 25% of the
calcemic effect of 1α25(OH)2D3.
6.2 Vitamin D analogs EB1089 and CB1093 combined with idarubicin
inhibited proliferation and promoted apoptosis in HL-60 leukemia cells (II)
Combined use of vitamin D analogs and IDA effectively inhibits HL-60 cell
proliferation
To study whether combining novel vitamin D analogs with IDA would inhibit
HL-60 cell proliferation more effectively than IDA alone, methylcellulose
colony forming assays were performed in various concentrations of these drugs
(Table 3). Untreated control HL-60 cells formed 301±12 colonies on petri dishes.
IDA alone at concentration 10-12 M permitted growth of 270±8 colonies whereas
at concentration 10-10 M or higher, all colony forming was prevented.
Combining vitamin D analog, EB1089, at concentration 10-10 M with IDA
decreased the number of colonies to 200±14 (p<0.0001) whereas higher
concentration at 10-8 M further inhibited the growth to 61±4 colonies (p<0.0001).
Similar results were observed with another vitamin D analog, CB1093, where
169±9 colonies (10-10 M), and 73±3 colonies (10-8 M) were formed (p<0.0001).
However, the inhibition of cell proliferation was more pronounced in any of
the treatment groups than in untreated controls (p<0.0001). In addition, when
comparing efficacy of these two vitamin D analogs without IDA, CB1093
showed to be more effective than EB1089 in preventing colony forming at
concentration 10-8 M (p<0.0001).
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Table 3
Cell proliferation, as measured with methyl cellulose colony forming assays. The results are
expressed as number of cell colonies (>40 cells), counted under inverted microscope. Mean
values of three experiments ± SD, each done in triplicate.
EB1089 10-8 M EB1089 10-10 M CB1093 10-8 M CB1093 10-10M No vitamin D
analog
No Ida 110 ± 9 243 ± 6 90 ± 4 228 ± 7 301 ± 12
Ida 10-12 M 61 ± 4 200 ± 14 73 ± 3 169 ± 9 270 ± 8
Ida 10-11 M 9 ± 3 21 ± 1 5 ± 2 14 ± 3 50 ± 3
Ida 10-10 M 0 0 0 0 0
Ida 10-9 M 0 0 0 0 0
In conclusion, combining vitamin D analogs, EB1089 or CB1093 with IDA
inhibited more effectively HL-60 cell proliferation and colony forming than
using IDA alone.
Vitamin D analogs induce apoptosis rather than necrosis  in HL-60 cells
This experiment aimed to study the effects of sequential treatment with a
vitamin D analog and IDA. The cells were first incubated with the analog for 72
h. IDA was then added and incubation continued for 48 h. The results are
expressed as the percentage of live, dead and apoptotic cells, as counted with
flow cytometry (Table 4).
Preincubation of HL-60 cells with vitamin D analogs, EB1089 or CB1093,
induced programmed cell-death, i.e., apoptosis in 80% and 72% of the cells,
respectively, compared to 30% in untreated controls (p<0.0001). At the same
time, the pool of dead cells was decreased from 8% to 4% or 3%, respectively
(p<0.001). Vitamin D analogs were tested in two different concentrations, 10-8
and 10-10 M. EB1089 significantly increased the number of apoptotic cells in
both concentrations compared to untreated controls. In contrast, CB1093 was
effective only in the higher concentration.
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 Table 4
The results are expressed as the percentage of cells ± SD, as counted with flow cytometry.
Apoptotic EB1089 10-8 M EB1089 10-10 M CB1093 10-8 M CB1093 10-10M No vitamin D
analog
No Ida 80.2 ± 4.5 44.4 ± 1.1 72.3 ± 0.7 26.8 ± 0.4 29.8 ± 0.6
Ida 10-12 M 73.1 ± 1.1 57.0 ± 1.3 73.0 ± 0.8 38.5 ± 0.8 32.6 ± 0.3
Ida 10-11 M 80.0 ± 1.8 47.6 ± 0.8 77.0 ± 0.5 31.0 ± 4.9 27.9 ± 0.4
Ida 10-10 M 81.4 ± 0.6 71.3 ± 1.1 79.6 ± 0.4 67.9 ± 3.6 67.3 ± 0.7
Ida 10-9 M 7.1 ± 0.1 2.0 ± 0.1 3.7 ± 0.2 2.8 ± 0.2 1.7 ± 0.3
Necrotic EB1089 10-8 M EB1089 10-10 M CB1093 10-8 M CB1093 10-10M No vitamin D
analog
No Ida 4.3 ± 0.5 4.5 ± 0.5 3.0 ± 0.2 2.7 ± 0.4 7.9 ± 0.2
Ida 10-12 M 2.9 ± 0.1 6.7 ± 0.2 3.9 ± 0.3 2.0 ± 0.2 5.4 ± 0.2
Ida 10-11 M 3.6 ± 0.6 7.9 ± 0.7 2.2 ± 0.1 4.6 ± 0.7 5.9 ± 0.4
Ida 10-10 M 11.0 ± 0.2 13.7 ± 0.5 8.0 ± 0.4 8.2 ± 0.5 20.9 ± 0.4
Ida 10-9 M 91.9 ± 0.3 90.6 ± 0.4 93.4 ± 0.5 93.5 ± 0.6 90.3 ± 0.2
Live EB1089 10-8 M EB1089 10-10 M CB1093 10-8 M CB1093 10-10M No vitamin D
analog
No Ida 15.2 ± 2.6 44.4 ± 0.8 24.4 ± 0.5 67.9 ± 0.7 60.7 ± 0.4
Ida 10-12 M 23.6 ± 0.8 35.8 ± 2.2 22.9 ± 0.4 57.8 ± 0.4 60.3 ± 0.4
Ida 10-11 M 16.0 ± 0.8 43.3 ± 0.8 20.6 ± 0.4 61.5 ± 7.4 62.0 ± 0.4
Ida 10-10 M 7.2 ± 0.2 14.6 ± 1.3 12.2 ± 0.3 23.6 ± 3.4 11.5 ± 0.3
Ida 10-9 M 0.9 ± 0.1 0.5 ± 0.1 2.2 ± 0.3 0.8 ± 0.2 0.4 ± 0.1
When using IDA alone at concentrations 10-12 M and 10-11 M it appeared to be
ineffective, at concentration 10-10 M the increase in the pool of apoptotic cells
was observed (30% vs. 67%). This was, however, associated with a rapid
increase in the number of dead cells as well (8% vs. 21%). At concentration
above 10-10 M IDA appeared to be cytotoxic killing 90% of the cells. Taken
together, the optimal concentration for IDA showed to be 10-10 M in this
experiment.
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When pretreating the HL-60 cells with EB1089 10-8 M or CB1093 10-8 M the
number of apoptotic cells increased compared to IDA alone (81% or 80% vs.
67%, p<0.0001). This effect was not , however, significantly better than using
EB1089 10-8 M alone (80%, p=0.3825). More importantly, the cell death induced
by IDA was significantly decreased by pretreatment (21% vs. 11% or 8% dead
cells, respectively, p<0.0001). Number of live cells was similar in all groups.
These experiments have demonstrated that novel vitamin D analogs, EB1089
and CB1093 were effective in inducing programmed cell-death in HL-60 cells.
Pretreating the cells with analogs prior to the exposure to IDA decreased the
number of necrotic dead cells, while simultaneously increasing apoptosis.
6.3 MC1288, inhibits adventitial inflammation and suppresses intimal
lesions in rat aortic allografts (III)
Effect of MC1288 on rat mixed lymphocyte culture (MLC)
We initially tested the effect of MC1288 on lymphocyte proliferation in vitro
using MLC. Rat MLC demonstrated that MC1288 was 100-fold more effective
than native vitamin D in suppressing stimulated lymphocytes in vitro.
Effect of MC1288 and CsA on allograft arteriosclerosis
To evaluate the effect of MC1288 on preventing acute and chronic rejection in
vivo we performed rat aortic allografts. The rats were treated either with
MC1288 or CsA alone or in combination. Even as late as three months after
transplantation, there was still some adventitial inflammation. Disappearance
of media cells (smooth muscle cells) and development of intimal thickening
with an increase in cellularity in the neointima was observed in nontreated
allografts. The MC1288+CsA treatment suppressed these manifestations of
allograft arteriosclerosis, although it did not abolish them completely.
Administration of MC1288 or CsA alone slightly decreased the number of
inflammatory cells in the adventitial layer of the graft. However, the most
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effective inhibition was obtained when MC1288 and CsA were combined. The
number of cells in the adventitia decreased from 10.0±0.9 to 4.1±1.0 psu,
p<0.01. Another manifestation of allograft arteriosclerosis, disappearance of
SMC in media, was almost completely abolished by all treatment groups. In
addition, the most important feature of allograft arteriosclerosis clinically,
intimal thickening, was decreased in all treatment groups. MC1288 or CsA
alone decreased intimal thickening from 2.5±0.3 to 0.8±0.2 psu respectively,
p<0.01, and combined treatment to 1.1±0.4 psu.
Proliferation assay of adventitial cells in vivo
To evaluate the effect of MC1288 on lymphocyte proliferation in vivo we
administrated BrdU and detected with immunoperoxidase staining the number
of positive cells in cross section. MC1288+CsA treatment did not only
decreased the number of adventitial cells but also their replication activity from
140±36 to 20±19 labeled cells/cross section at one month after transplantation.
However, there was no longer any difference in proliferation rate at three
months.
Inflammatory pattern of adventitial cells modified by MC1288
The pattern of adventitial inflammatory cells was investigated at one month
after transplantation. Treatment with MC1288 decreased the number of cells
expressing interleukin 2 receptor (IL-2R) from 156±32 to 90±21 positive
cells/cross section in the vascular wall, as well as the intensity of the staining of
T helper cells (CD4). The expression of cytotoxic T cells (CD8) was not affected
but the expression of macrophage marker ED1 was slightly upregulated.
Side-effects
MC1288 did not induce hypercalcemia during the first month of treatment, but
in the long term experiment (3 months), the serum calcium level increased from
2.4±0.1 mmol/l (age-matched nontreated controls) to 3.2±0.2 mmol/l, p<0.05,
in the MC1288 group, and to 3.3±0.3 mmol/l, p<0.05, after combined treatment
with MC1288+CsA. Thus adding CsA into the protocol did not affect the
induction of hypercalcemia.
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Another side-effect observed was that the animals treated with MC1288 or
MC1288+CsA lost weight during three weeks from 197±27 to 160±26 grams
(18.5%) and from 155±16 to 147±18 grams (4.7%), respectively. During the
observation time untreated control animals remained the same weight (198±18
grams). One of MC1288 treated animals was lost before the end of follow-up
time due to hypercalcemia and cachexia.
6.4 MC1288, a vitamin D analog, prevents acute graft-versus-host disease in
rat bone marrow transplantation (IV)
MC1288 effectively suppressed GVHD related dermatitis
Acute GVHD manifests first and most commonly in the skin. After allogeneic
BMT, the untreated control group showed signs of dermatitis in the paws and
the erythema of the ears from day five onwards. The animals began to lose hair
on day 11. The CsA treated group showed similar, although milder, signs of
GVHD within the same time frame. Rats that received MC1288 or the
combined treatment with CsA showed none of the above signs of GVHD.
All animals developed mild diarrhea by day 9. In addition, they lost some
weight. Before BMT, the recipient rat weights were 255± 40g, but decreased to
191±14 g in the untreated, to 219±25 g in the CsA, to 228±39 g in the MC1288
and to 225±27 g in the combined treatment group. Taken together, MC1288
effectively suppressed the clinical signs of GVHD, i.e., dermatitis, weight loss
and hair loss in rats after BMT.
MC1288 suppressed histological manifestations of GVHD
Within 20 days after BMT, the untreated rats developed classical signs of
GVHD in various organs (Figure 3). In the liver, the portal tracts were enlarged
and affected by moderate inflammatory infiltration and edema, and there was
mild cholangitis. In contrast, in the MC1288 treated animals the portal tracts
were only slightly enlarged with little to no inflammation or destruction, but
with mild inactive fibrosis in the background.
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To assess the degree of GVHD, we graded these histologic alterations of GVHD
in the skin, liver , and spleen in different treatment groups as a mean total
increment. The groups treated with MC1288, either alone, or in combination
with CsA, had a significantly lower mean total increment (1.4±0.5 and 1.1±0.6,
respectively) compared to the untreated animals (5.0±1.6, p<0.001 for both).
CsA alone was slightly beneficial (3.5±1.0, p=ns), albeit not significantly,
compared to the untreated rats.
Taken together, these results show that a novel vitamin D analog, MC1288, was
effective in preventing histological manifestations of acute GVHD in the skin,
liver , and spleen. MC1288 was more effective than CsA alone in preventing
GVHD, but when combined these two drugs may have even additive effects.
MC1288 suppressed immune cells more effectively than CsA in BMT
To study the effect of MC1288 on effector T-cells and macrophage activation,
immunohistochemistry was performed on frozen sections of liver and skin and
quantified. The results are summarized in Table 5.
In the liver, MC1288 markedly suppressed the expression of CD4 positive cells.
The effect was more pronounced when combined with CsA. MC1288 and CsA
were equally effective in suppressing CD8 positive cells. However, when the
animals were treated with the combination of these drugs, no CD8 positive
cells were found. The findings were similar in the MHC class II expressing
cells. IL-2 receptor (IL-2R) expression was strongly suppressed after MC1288
treatment as well as after CsA and CsA+MC1288 treatments. Nitric oxide
synthase 2 (NOS2) in the liver was suppressed in all treatment groups. The
expression of natural killer cells (NKR-P1A) was markedly suppressed with the
combination therapy, whereas MC1288 alone had a lesser effect. The number of
NK cells in the CsA group was slightly elevated compared to the untreated
group. To summarize, MC 1288 effectively suppressed CD4, CD8, MHC class
II, IL-2R , and NOS2 expression in the liver.
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Table 5.  Expression of inflammatory markers in liver and skin after BMT. Data is expressed
as the number of positive cells/high power field ±SD where *p<0.001 comparing to untreated
group.
MC1288 MC1288+CsA untreated CsA
Liver
CD4 2.2±0.3* 0.8±0.2* 6.4±0.6 3.4±0.2*
CD8 0.8±0.2* 0.0±0.0* 3.6±0.3 0.8±0.1*
MHC class II 11.7±0.4* 7.3±0.2* 23.2±0.9 13.6±1.2*
IL-2R 0.0±0.0* 0.1±0.0* 1.3±0.1 0.0±0.0*
NOS2 0.1±0.1* 0.0±0.0* 1.2±0.2 0.0±0.0*
NKR-P1A 0.3±0.0 0.0±0.0* 0.4±0.0 0.6±0.1*
Skin
CD4 0.4±0.1* 0.2±0.1* 2.8±0.4 0.6±0.1*
CD8 0.0±0.0* 0.0±0.0* 1.3±0.2 1.2±0.2
MHC class II 3.6±0.5* 1.6±0.1* 13.4±3.0 4.7±0.3*
IL-2R 0.1±0.1* 0.0±0.0* 2.2±0.2 0.9±0.3*
NOS2 0.1±0.1* 0.7±0.1* 1.1±0.1 1.7±0.1*
NKR-P1A 0.0±0.0* 0.0±0.0* 1.9±0.2 0.2±0.0*
In the skin, MC1288 markedly suppressed the expression of CD4 positive cells
but the effect was more pronounced when combined with CsA. CD8 positive
cells were totally suppressed by MC1288. CsA did not have a significant effect
on CD8 cells in the skin. The MHC II expression in the skin was very similar to
the liver. MC1288 proved to be very effective in suppressing class II expression
with a further improved effect in combination therapy. IL-2R expression was
also significantly suppressed in the skin after MC1288 treatment. NOS2
expression in the skin was markedly decreased by MC1288. Interestingly, in the
skin, CsA treatment caused an unexpected elevation of NOS2 expression as
opposed to the effect in the liver. This finding was concordant with the fact that
combination treatment showed more positivity than MC1288 alone. NK cells
were absent in both of the MC1288 treated groups and the CsA alone group
was also significantly lower. In summary, MC1288 effectively suppressed CD4,
CD8, MHC class II, IL-2R, NKR-P1A , and NOS2 expression in the skin 20 days
after allogeneic BMT.
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DISCUSSION
7.1 Low calcemic activity and good antileukemic potential make CB1093 a
promising candidate for phase I clinical studies
We had previously shown that EB1089 is one of the most potent inducers of
differentiation of HL-60 cells (Pakkala et al., 1995). The novel analog CB1093
proved to be an even more potent differentiating agent than EB1089. The
comparison of the efficacy of the analogs on the colony forming potential and
DNA synthesis of HL-60 cells showed CB1093 also to have the highest capacity
to inhibit leukemic cell growth. The ED50 values for 1α25(OH)2D3 and EB1089
were comparable with results reported previously. Thus, it was possible to
make comparisons also with analogs reported elsewhere (Zhou et al., 1989).
So far only two analogs (EB1089 and 1,25(OH)2-16ene-23yne-D3) tested both in
vitro and in vivo had shown promise for clinical trials. It is important to notice
that for therapeutic purposes a vitamin D analog has to show not only good
differentiating capacity and antileukemic effect but also low calcemic effect.
CB1093 was at least equally effective as the best analogs reported so far in
inducing differentiation of HL-60 cells. It was even more effective against de
novo AML cells. The consistent effect against AML cells suggested that CB1093
might have antileukemic potency also in vivo. CB1093 is better tolerated than
most vitamin D analogs. The best antileukemic analog so far has been EB1089
but our study suggested that CB1093 could be given in doses ten times higher
than EB1089. This dose would result in antileukemic efficacy 100 times higher
than achieved with 1α25(OH)2D3, assuming that the pharmacokinetics are
comparable. Comparison to other analogs tested in our study or reported
previously also demonstrated the superiority of CB1093.
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7.2 The combination of EB1089 or CB1093 with idarubicin
CR rates achieved with different combinations of cytarabine and
anthracyclines have been unimproved over the past decade. A novel
approach to improve the CR rates would be the combination of existing
anthracycline therapy  with differentiation therapy as used in APL.
APL differs from all other AML subtypes due to its unique 15;17
translocation. Differentiation therapy is targeted to the disrupted gene
function of this translocation. Noncalcemic vitamin D analogs EB1089 and
CB1093 have antileukemic effects in vitro on different AML subtypes and
could extend the differentiation therapy to other AML subtypes as well. We
demonstrated in this experiment that combination treatment of EB1089 or
CB1093 with IDA inhibited more effectively the proliferation and colony
forming of HL-60 cells than IDA alone. This would allow the reduction of
anthracycline doses, and thereby reduce the adverse cardiotoxic effects of
these drugs without jeopardizing the remission rates.
Alternatively, one could use vitamin D analog  sequentially with
anthracyclines to utilize the differentiation promoting properties of vitamin D
analogs. Some recent studies have reported that induction of differentiation is
associated with increased resistance to apoptosis-inducing agents, such as
chemotherapy and γ-irradiation (Ketley et al., 1997). Our studies supported
this notion. We demonstrated that preincubation of HL-60 cells with vitamin
D analogs EB1089 or CB1093 prior to exposure to IDA induced significantly
more programmed cell-death, i.e., apoptosis in these cells. However,
compared to the effect of vitamin D analogs alone the effect on apoptosis was
not enhanced. At the same time the number of necrotic cells was slightly
diminished.
These experiments have demonstrated that novel vitamin D analogs, EB1089
and CB1093 were effective in inducing programmed cell death in HL-60 cells.
Pretreating the HL-60 cells with vitamin D analogs prior to the exposure to
IDA decreased the number of necrotic cells, while simultaneously increasing
apoptosis. Combining vitamin D analogs, EB1089 or CB1093 with IDA
inhibited HL-60 cell proliferation and colony forming more effectively  than
using IDA alone.
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In conclusion, these findings suggest that novel vitamin D analogs EB1089 or
CB1093 used in combination with IDA may enhance the antileukemic effect.
This could either be used to improve the CR rates, or to reduce the dose of
cytotoxic medication, thus reducing their adverse effects. On the other hand
sequential use of EB1089 or CB 1093 with IDA may not result in enhanced
apoptotic effect but may instead abrogate the effects of IDA. Whether this
effect is due to the diminished nucleic acid synthesis in differentiated cells
requires further study.
7.3 MC1288 is effective in the treatment of both acute and chronic rejection
Several new immunosuppressive molecules have been developed in recent
years.  The aim has been to find a new immunosuppressive drug with fewer
adverse effects than those currently used.  The tendency seems to be that by
combining drugs, the doses can be lowered and side-effects avoided.  A
recent candidate is a vitamin D analogue, MC1288, which could provide a
new therapeutic approach in organ transplantation.
When we had shown with rat MLC that MC1288 is immunosuppressive in
vitro, we tested the drug also in vivo. In our rat aortic allograft model, acute
rejection occurs during the first month after transplantation. MC1288
combined with CsA effectively suppressed adventitial inflammatory response
by reducing the number of cells and their replication rate in the adventitia of
the graft.  Our finding of suppression of adventitial inflammatory response in
the vascular wall extends earlier studies in which MC1288 prevented acute
rejection and prolonged allograft survival in rat heart transplantation, and
small bowel transplantation (Johnsson and Tufveson, 1994) .
The number of cells expressing IL-2R was downregulated by MC1288,
reflecting a decrease in the number of inflammatory cells in the adventitia,
possibly due to inhibition of IL-2R generation, as has been demonstrated
earlier (Lemire et al., 1985). As MC1288 binds to the same vitamin D receptor
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as native 1α25(OH)2D3, it was expected to bind to activated T cells, thus
inhibiting IL-2 production on the transcriptional level (Bhalla et al., 1984;
Lemire et al., 1985; Rigby et al., 1984).
The expression of CD4 positive cells was also downregulated, indicating they
might be targeted by MC1288.  This finding is concordant with earlier results
(Lemire et al., 1985; Rigby et al., 1990).  On the contrary, the expression of
cytotoxic T cells (CD8) was unaltered.  This may be expected as 1α,25(OH)2D3
does not affect class I HLA antigen expression on monocytes (Rigby et al.,
1990).
The expression of macrophage specific antigen (ED1) was somewhat
upregulated in MC1288-treated animals. Rigby et al. have demonstrated that
1α25(OH)2D3 reduces the ability of monocytes to induce antigen-dependent
T-cell proliferation. In Rigby´s model the addition of interleukin-1 (IL-1), IL-6,
or indomethacin did not restore antigen-dependent T-cell proliferation,
suggesting that this observation was not secondary to changes in IL-1, IL-6, or
PGE2 production induced by 1α25(OH)2D3 . These data suggest that
1α25(OH)2D3 treatment specifically modulates human monocyte phenotype
and function, altering HLA-DR antigen expression and antigen presentation,
while leaving lytic function intact. (Rigby et al., 1990).  This may be an
additional pathway that contributes to the inhibition of inflammatory
response seen in aortic allografts.
Chronic rejection fully develops three months after transplantation in our
model. The typical features, disappearance of smooth muscle cells in media
and intimal thickening, were both significantly reduced by either MC1288 or
CsA alone or by their combination. This reduction may be due to the
relatively high mean concentration of CsA (300-900 ng/ml) during the
experiment. It has been demonstrated that there is strong inverse correlation
between CsA concentration and development of intimal lesions in rat heart
allografts (Koskinen et al., 1995). Thus the novelty of our result was that
MC1288 not only prolonged graft survival and prevented acute rejection but
also inhibited chronic rejection manifesting as intimal thickening in the
vascular wall that ultimately leads to occlusion of vessel and graft loss.
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7.4 MC1288 prevents acute graft-versus-host disease in rat bone marrow
transplantation
We discovered several new findings with the bone marrow transplant model
of our laboratory. First, a novel vitamin D analog, MC1288, either alone or in
combination with CsA, prevented clinical signs of GVHD after allogeneic
bone marrow transplantation. Second, the histological features of GVHD, i.e.
epidermal vacuolar degeneration, portal small lymphocyte infiltration, bile
duct injury, edema, fibrosis, and appearance of megakaryocytes in the spleen,
were significantly suppressed in MC1288 treated rats. Third, MC1288
effectively suppressed CD4 and CD8 positive T cells, NK cells, MHC class II,
IL-2R , and NOS2 expression in the skin and liver, suggesting that MC1288
acts through T and NK cell and macrophage suppression.
Immunopathogenesis of GVHD can be divided into three phases: I) recipient
conditioning, II) donor T cell activation, , and III) inflammatory effectors
(Krenger et al., 1997). In phase I, host conditioning including total body
irradiation or chemotherapy leads to damage and activation of host tissues,
which causes increased secretion of inflammatory factors like LPS, tumor
necrosis factor α (TNF- α) or interleukin-1 (IL-1) and IL-6.
In phase II, host alloantigens activate donor T cells that differentiate and
proliferate into Th1 and/or Th2 type subsets. Specifically, Th1 type cytokine
(IFN-γ and IL-2) responses have been postulated to be responsible for GVHD
through controlling and amplifying immune cells: CD4+ and CD8+ T cells,
NK cells , and monocytes (Krenger et al., 1997). Recently, it has been shown
that both Th1 and Th2 type cytokines mediate acute GVHD with distinct end-
organ targets (Nikolic et al., 2000). Using STAT4 gene deficient mice that
induce Th2 type immune response, as BMT donors, mainly caused liver and
skin manifestations of acute GVHD in the recipients. In contrast, intestinal
manifestations of GVHD were the major observation in the recipients that
received BMT from STAT6 gene deficient mice mounting Th1 type cytokine
response. This study clearly demonstrated that both Th1 and Th2 responses
are necessary for the development of GVHD. Our study showed that MC1288
effectively decreased the number of CD4+ and CD8+ cells and IL-2 receptor
expression in the liver and skin. Whether MC1288 selectively down-regulated
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either Th1 or Th2 type cytokine producing cells, or both of them, remains
open.
Phase III of acute GVHD culminates in the effector functions that lead to full
spectrum of deleterious effects including cachexia and target cell destruction
in different organs (Krenger et al., 1997). Mediators of these lesions include
inflammatory cytokines and nitric oxide, macrophages/monocytes, NK cells,
specific anti-host cytotoxicity mediated by cytotoxic lymphocytes through Fas
and perforin apoptotic pathways. We demonstrated that MC1288 effectively
decreased both NK cell (NKR-P1A) and NOS2 expression in the liver and skin
after BMT suggesting that MC1288  only not influences phase II T cell
activation but also suppresses the effector phase.
All in all, the vitamin D analog MC1288 down-regulated both the donor T cell
activation (phase II) and inflammatory effector mechanisms (phase III) of
acute GVHD after major mismatched allogeneic BMT. MC1288 was even
more effective in preventing GVHD when combined with CsA.
7.5 Use of vitamin D analogs as a remission prolonging agent
Low dose maintenance chemotherapy has not been effective in AML and most
patients still relapse. Contrary to chemotherapy, differentiating agents are able
to induce remission through maturation rather than direct cell kill. This
approach could also be effective in eradicating residual leukemia in remission.
Residual disease could be eradicated if cells which are resistant to
chemotherapy were terminally differentiated resulting to apoptosis. This is
suggested by the studies in mice transplanted with syngeneic leukemia cells
where vitamin D analogs enhanced the survival of mice with residual
leukemia. EB1089 is a very potent inhibitor of leukemic blasts without
suppressing the clonal growth of normal hematopoietic progenitor cells (Lee et
al., 1996). CB1093 proved to be even more effective in our study. Having
achieved remission, the patients could benefit from continuous therapy with
the well-tolerated vitamin D analogs. Their antileukemic effect could prevent
relapses. Most probably they would be suitable for maintenance therapy after
consolidation chemotherapy. Early results suggest, that vitamin D analog could
be administered already in the cytopenia stage of recovery, as it has no adverse
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effects on hematopoiesis. A phase I study has demonstrated that EB 1089 can
be given to AML patients for prolonged periods in oral doses ranging from 5 to
15 µg daily (Pakkala et al. manuscript in preparation).
7.6 Use of vitamin D analogs in immunosuppression
Novel vitamin D analogs may provide new therapeutic options in organ
transplantation. MC1288 has been very promising in experimental studies.
They are well tolerated, with hypercalcemia being the only major known side
effect. Combinations with other immunosuppressants (notably CsA) have been
no more hypercalcemic than MC1288 alone, making combination treatment
feasible at least in experimental studies.
Vitamin D analogs are especially attractive in stem cell transplantation.
Among the disadvantages of the currently-used pharmacological agents; CsA,
prednisone, methotrexate, and FK506 is that they produce generalized
immunosuppression and have a negative influence on the beneficial graft-
versus-leukemia effect. In contrast to these “traditional” immunosuppressive
drugs, vitamin D analogs have also demonstrated anti-leukemic effects in
vivo and in vitro. They have no ill effect on hematopoiesis and have in fact
been reported to stimulate the proliferation of normal human CD34+ cells
(Lee et al., 1996). However, different vitamin D analogs vary significantly in
their immunosuppressive, anti-leukemic, and calcemic properties, and
therefore further studies are required to assess the most suitable analog for
clinical studies.
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7.7 Future views
While the research on vitamin D analogs is making progress with promising
new analogs and reports regarding various diseases, we still lack the
fundamental understanding of the mechanism of action of these agents on a
molecular level. By understanding the precise chain of events within the
target cell, it would be possible to develop more useful analogs. Instead of
synthesizing hundreds of compounds to be meticulously screened, an analog
could be modeled specifically with the intended properties. In an ideal
situation we would have a very potent differentiating agent with minimal
calcemic and immunosuppressive effect to use as a remission-prolonging
agent. We would have one potent, well tolerated immunosuppressant with
minimal side effects for use in transplantation and in the treatment of
autoimmune diseases. The third ideal analog would combine the
immunosuppressive with differentiating properties, with minimal side effects
to be used in stem cell transplantation for acute leukemia. It would help to
eradicate residual leukemia while preventing graft versus host disease.
The understanding of the mechanisms on a molecular level could also
provide valuable information regarding the control of the cell cycle, cell
maturation and apoptosis.
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SUMMARY
The treatment of acute myeloid leukemia would decisively change with a
differentiation therapy suitable for clinical use.
The first aim of this study was to investigate the effects of vitamin D analogs on
the differentiation and growth of leukemia cells, and combinations of VD3
analogs with chemotherapy in vitro.
We studied the effects of 1α25(OH)2D3, and two novel vitamin D analogs:
EB1089 and CB1093 on HL-60 cells and de novo AML cells in vitro. CB1093 was
at least equally effective as the best analogs reported so far in inducing
differentiation of HL-60 cells. It was even more effective against de novo AML
cells.  CB1093 could be better tolerated than most vitamin D analogs due to it´s
low calcemic effect. The best antileukemic analog so far has been EB1089 but
our study suggested that CB1093 could be given in doses ten times higher than
EB1089, at least in rats. This dose would result in antileukemic efficacy 100
times higher than achieved with 1α25(OH)2D3, assuming that the
pharmacokinetics are comparable.
We also studied the effect of EB1089 and CB1093 alone, in combination, or in
sequence with idarubicin on HL-60 cells. EB1089 and CB1093 were effective in
inducing programmed cell death in HL-60 cells. Pretreating the HL-60 cells
with vitamin D analogs prior to the exposure to IDA decreased the number of
necrotic cells, while simultaneously increasing apoptosis. Combining vitamin
D analogs, EB1089 or CB1093 with IDA inhibited HL-60 cell proliferation and
colony forming more effectively  than using IDA alone.
Stem cell transplantation is common practice in leukemia for patients with a
suitable donor. Main problems arise from acute graft-versus-host disease. Due
to lack of suitable related donors the use of unrelated, HLA-matched donors
from international marrow-donor registries has increased. This has lead to a
better prognosis in the treatment of leukemia itself, due to graft-versus-
leukemia effect, but with the cost of higher incidence of GVHD.
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In solid organ transplantation many transplants are lost due to chronic
rejection (transplant arteriosclerosis). The medication used for chronic rejection
today has marked side effects that severely limit the immunosuppressive effect
that can be induced with these drugs.
The second aim of this study was to investigate vitamin D analogs in the
prevention of acute and chronic rejection in a solid organ transplant model,
and graft-versus-host disease in a BMT model in vivo.
We initially tested the effect of vitamin D analog MC1288 on lymphocyte
proliferation in vitro using mixed lymphocyte cultures. Rat MLC demonstrated
that MC1288 was 100-fold more effective than native vitamin D in suppressing
stimulated lymphocytes in vitro. To evaluate the effect of MC1288 on
preventing acute and chronic rejection in vivo we performed rat aortic
allografts that were treated either with MC1288 or cyclosporin A alone or in
combination. In our rat aortic allograft model, acute rejection occurs during the
first month after transplantation. MC1288 combined with CsA effectively
suppressed adventitial inflammatory response by reducing the number of cells
and their replication rate in the adventitia of the graft. Chronic rejection
develops fully three months after transplantation in our model. The typical
features, disappearance of SMC in media and intimal thickening, were both
significantly reduced by either MC1288 or CsA alone, or by their combination.
Prevention of graft-versus-host disease was investigated in a major
mismatched allogeneic rat bone marrow transplant model. MC1288, either
alone or in combination with CsA, prevented clinical signs of GVHD after
allogeneic bone marrow transplantation. The histological features of GVHD,
i.e. epidermal vacuolar degeneration, portal small lymphocyte infiltration, bile
duct injury, edema, fibrosis, and appearance of megakaryocytes in the spleen,
were significantly suppressed in MC1288 treated rats. MC1288 effectively
suppressed CD4 and CD8 positive T cells, NK cells, MHC class II, IL-2R , and
NOS2 expression in the skin and liver, suggesting that MC1288 acts through T
cell, NK cell, and macrophage suppression.
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